Director at C4 Therapeutics (CCCC) takes 3,341 shares as fees

Rhea-AI Filing Summary

GROGAN DONNA ROY reported acquisition or exercise transactions in this Form 4 filing.

C4 Therapeutics director Donna Roy Grogan received a grant of 3,341 shares of common stock on July 1, 2026. The shares were issued under the company’s Non-Employee Director Compensation Policy, as she elected stock instead of cash fees, bringing her direct holdings to 74,853 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GROGAN DONNA ROY

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,341	$4.34	$14K

Holdings After Transaction: Common Stock — 74,853 shares (Direct, null)

Footnotes (1)

1. These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2026.

Key Figures

Shares granted: 3,341 shares Grant valuation price: $4.34 per share Shares held after transaction: 74,853 shares

3 metrics

Shares granted 3,341 shares Common stock grant on July 1, 2026

Grant valuation price $4.34 per share Closing market price on July 1, 2026

Shares held after transaction 74,853 shares Total direct ownership after grant

Key Terms

Non-Employee Director Compensation Policy, grant/award acquisition, closing market price

3 terms

Non-Employee Director Compensation Policy financial

"These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy"

grant/award acquisition financial

"transaction_action: "grant/award acquisition" and transaction_code_description"

closing market price financial

"The price reported in Column 4 is based upon the closing market price"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:05 PM Accepted by SEC EDGAR 07/02/2026 - 04:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GROGAN DONNA ROY

(Last) (First) (Middle)

C/O C4 THERAPEUTICS, INC.

490 ARSENAL WAY #120

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		A(1)		3,341	A	$4.34(2)	74,853	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2026.

Remarks:

	/s/ Shagha Russell, Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did C4 Therapeutics (CCCC) report for Donna Roy Grogan?

C4 Therapeutics reported that director Donna Roy Grogan received 3,341 shares of common stock on July 1, 2026. The shares were issued as part of her non-employee director compensation instead of a cash payment for board service.

Was the C4 Therapeutics (CCCC) Form 4 transaction an open-market purchase or a grant?

The Form 4 shows a grant/award acquisition, not an open-market purchase. Grogan elected to receive shares in lieu of cash under the company’s Non-Employee Director Compensation Policy for her work as a non-employee director.

At what price was the C4 Therapeutics (CCCC) director stock grant valued?

The 3,341-share grant to Donna Roy Grogan was valued at $4.34 per share. The filing notes this price reflects the closing market price of C4 Therapeutics common stock on July 1, 2026, the date of issuance.

How many C4 Therapeutics (CCCC) shares does Donna Roy Grogan hold after this Form 4 transaction?

After the grant, Donna Roy Grogan directly holds 74,853 shares of C4 Therapeutics common stock. This total includes the newly issued 3,341 shares received as non-cash board compensation under the company’s Non-Employee Director Compensation Policy.

Why did C4 Therapeutics (CCCC) issue shares instead of cash to the director?

The shares were issued under the company’s Non-Employee Director Compensation Policy. Under this policy, the reporting person elected to receive common stock instead of cash as compensation for serving as a non-employee director of C4 Therapeutics.